Validating the rigour of adaptive methods of economic evaluation
AS Chauhan, D Sharma, A Mehndiratta, N Gupta… - BMJ Global …, 2023 - gh.bmj.com
Background There has been a lot of debate on how to 'generalise'or 'translate'findings of
economic evaluation (EE) or health technology assessment (HTA) to other country contexts …
economic evaluation (EE) or health technology assessment (HTA) to other country contexts …
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a …
SM Khoirunnisa, FDA Suryanegara… - Expert Review of …, 2024 - Taylor & Francis
Introduction This study aims to provide a comprehensive assessment of economic and
health-related quality of life (HRQoL) outcomes for human epidermal growth factor receptor …
health-related quality of life (HRQoL) outcomes for human epidermal growth factor receptor …
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study
MH Park, JH Seo, JH Park, MK Seong… - Expert opinion on …, 2024 - Taylor & Francis
Background The trastuzumab biosimilar CT-P6 is approved for human epidermal growth
factor receptor 2 (HER2)–positive early breast cancer (EBC), metastatic breast cancer …
factor receptor 2 (HER2)–positive early breast cancer (EBC), metastatic breast cancer …
[引用][C] A decade of HTA in Indonesia: Methodological challenges in conducting economic evaluation
S Putri, LS Masytoh - Health Policy and Technology, 2024 - scholar.ui.ac.id
A decade of HTA in Indonesia: Methodological challenges in conducting economic evaluation
— Universitas Indonesia Skip to main navigation Skip to search Skip to main content …
— Universitas Indonesia Skip to main navigation Skip to search Skip to main content …